• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺癌放疗后生存的预后因素-吸烟包年数的影响。

Prognostic Factors of Survival After Radiotherapy for Lung Cancer-The Impact of Smoking Pack Years.

机构信息

Department of Radiation Oncology, University of Lübeck, Lübeck, Germany.

Department of Pulmonology, University of Lübeck, Lübeck, Germany.

出版信息

In Vivo. 2022 May-Jun;36(3):1297-1301. doi: 10.21873/invivo.12830.

DOI:10.21873/invivo.12830
PMID:35478154
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9087111/
Abstract

BACKGROUND/AIM: The prognostic role of smoking pack years after thoracic irradiation for lung cancer needs further clarification, since previous studies showed conflicting results. Therefore, this study investigated potential prognostic factors for survival including pack years in 170 lung cancer patients receiving local radiotherapy.

PATIENTS AND METHODS

Twelve factors were retrospectively evaluated for survival including age, sex, tumor site, histology, primary tumor stage, nodal stage, distant metastasis, radiation dose, upfront surgery or systemic treatment, pulmonary function, and number of pack years.

RESULTS

On univariate analyses, absence of distant metastasis (p=0.049), radiation dose >56 Gy (p=0.019), and ≤40 pack years (p=0.005) were significantly associated with better survival. In the multivariate analysis, number of pack years (hazard ratio 2.18, 95% confidence interval 1.25-3.82, p=0.006) maintained significance; distant metastasis (p=0.34) and radiation dose (p=0.16) were not significant.

CONCLUSION

Number of pack years was an independent predictor of survival after thoracic irradiation for lung cancer.

摘要

背景/目的:肺癌患者接受胸部放疗后吸烟包年数的预后作用仍需进一步阐明,因为先前的研究结果存在矛盾。因此,本研究调查了 170 例接受局部放疗的肺癌患者的生存相关潜在预后因素,包括吸烟包年数。

患者和方法

回顾性评估了 12 个因素与生存的关系,包括年龄、性别、肿瘤部位、组织学、原发肿瘤分期、淋巴结分期、远处转移、放疗剂量、术前手术或全身治疗、肺功能和吸烟包年数。

结果

单因素分析显示,无远处转移(p=0.049)、放疗剂量>56Gy(p=0.019)和≤40 包年(p=0.005)与生存时间延长显著相关。多因素分析显示,吸烟包年数(风险比 2.18,95%置信区间 1.25-3.82,p=0.006)仍有统计学意义;远处转移(p=0.34)和放疗剂量(p=0.16)无统计学意义。

结论

吸烟包年数是肺癌患者接受胸部放疗后生存的独立预测因素。

相似文献

1
Prognostic Factors of Survival After Radiotherapy for Lung Cancer-The Impact of Smoking Pack Years.肺癌放疗后生存的预后因素-吸烟包年数的影响。
In Vivo. 2022 May-Jun;36(3):1297-1301. doi: 10.21873/invivo.12830.
2
Prognostic impact of VEGF and VEGF receptor 1 (FLT1) expression in patients irradiated for stage II/III non-small cell lung cancer (NSCLC).血管内皮生长因子(VEGF)和血管内皮生长因子受体 1(FLT1)表达对接受放疗的 II/III 期非小细胞肺癌(NSCLC)患者预后的影响。
Strahlenther Onkol. 2010 Jun;186(6):307-14. doi: 10.1007/s00066-010-2131-4. Epub 2010 Apr 26.
3
Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.吸烟对携带激活型表皮生长因子受体(EGFR)突变的肺腺癌患者表皮生长因子受体(EGFR)-酪氨酸激酶抑制剂治疗反应的影响。
Lung Cancer. 2014 May;84(2):196-202. doi: 10.1016/j.lungcan.2014.01.022. Epub 2014 Feb 3.
4
Fibroblast growth factor 2--a predictor of outcome for patients irradiated for stage II-III non-small-cell lung cancer.成纤维细胞生长因子 2——预测 II-III 期非小细胞肺癌放疗患者预后的标志物。
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):442-7. doi: 10.1016/j.ijrobp.2010.08.048. Epub 2010 Oct 14.
5
Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience.单纯放疗用于医学上无法手术的Ⅰ期非小细胞肺癌:杜克大学的经验。
Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):149-54. doi: 10.1016/s0360-3016(97)00589-0.
6
Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L.组织学和吸烟状况预测晚期非小细胞肺癌患者的生存。西日本肿瘤学组(WJOG)研究 3906L 的结果。
J Thorac Oncol. 2013 Jun;8(6):753-8. doi: 10.1097/JTO.0b013e31828b51f5.
7
Effectiveness of accelerated radiotherapy for patients with inoperable non-small cell lung cancer (NSCLC) and borderline prognostic factors without distant metastasis: a retrospective review.加速放疗对无法手术的非小细胞肺癌(NSCLC)且无远处转移的临界预后因素患者的疗效:一项回顾性研究。
Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1053-6. doi: 10.1016/s0360-3016(99)00130-3.
8
Neutrophil-to-Lymphocyte Ratio Predicts Outcome in Limited Disease Small-cell Lung Cancer.中性粒细胞与淋巴细胞比值可预测局限期小细胞肺癌的预后。
Lung. 2017 Apr;195(2):217-224. doi: 10.1007/s00408-017-9976-6. Epub 2017 Feb 2.
9
Results of high-dose thoracic irradiation incorporating beam's eye view display in non-small cell lung cancer: a retrospective multivariate analysis.采用射野内观显示的大剂量胸部放疗在非小细胞肺癌中的应用结果:一项回顾性多因素分析
Int J Radiat Oncol Biol Phys. 1993 Sep 30;27(2):273-84. doi: 10.1016/0360-3016(93)90238-q.
10
Smoking habits are an independent prognostic factor in patients with lung cancer.吸烟习惯是肺癌患者的一个独立预后因素。
Clin Respir J. 2017 Sep;11(5):579-584. doi: 10.1111/crj.12386. Epub 2015 Oct 7.

引用本文的文献

1
Harnessing Baseline Radiomic Features in Early-Stage NSCLC: What Role in Clinical Outcome Modeling for SBRT Candidates?利用早期非小细胞肺癌的基线放射组学特征:在立体定向体部放疗候选患者的临床结局建模中起什么作用?
Cancers (Basel). 2025 Mar 6;17(5):908. doi: 10.3390/cancers17050908.

本文引用的文献

1
Improving Outcomes in NSCLC: Optimum Dose Fractionation in Radical Radiotherapy Matters.改善非小细胞肺癌的治疗结果:根治性放疗中的最佳剂量分割至关重要。
J Thorac Oncol. 2022 Apr;17(4):532-543. doi: 10.1016/j.jtho.2022.01.006. Epub 2022 Jan 31.
2
Cancer statistics, 2022.癌症统计数据,2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
3
Radiation Pneumonitis After Volumetric Modulated Arc Therapy for Non-small Cell Lung Cancer.容积调强弧形治疗非小细胞肺癌后的放射性肺炎。
Anticancer Res. 2021 Nov;41(11):5793-5802. doi: 10.21873/anticanres.15396.
4
Hypofractionated Proton Beam Therapy for cT1-2N0M0 Non-small Cell Lung Cancer Patients With Interstitial Lung Disease.间质性肺病 cT1-2N0M0 期非小细胞肺癌患者的适形调强质子治疗。
Anticancer Res. 2021 Nov;41(11):5635-5642. doi: 10.21873/anticanres.15379.
5
Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis.二代和三代表皮生长因子受体酪氨酸激酶抑制剂作为非小细胞肺癌一线治疗的比较:一项回顾性分析。
Anticancer Res. 2021 Oct;41(10):5137-5145. doi: 10.21873/anticanres.15331.
6
Comparison of Dose Distribution Between VMAT-SBRT and Scanning Carbon-ion Radiotherapy for Early-stage NSCLC.早期非小细胞肺癌容积旋转调强放疗与扫描碳离子放疗的剂量分布比较。
Anticancer Res. 2021 Sep;41(9):4571-4575. doi: 10.21873/anticanres.15270.
7
Systemic Inflammatory Score Predicts Response and Prognosis in Patients With Lung Cancer Treated With Immunotherapy.系统炎症评分预测免疫治疗肺癌患者的反应和预后。
Anticancer Res. 2021 Jul;41(7):3673-3682. doi: 10.21873/anticanres.15158.
8
The Prognostic Value of Programmed Death-ligand 1 (PD-L1) in Patients who Received Neoadjuvant Chemoradiation Therapy Followed by Surgery for Locally Advanced Non-small Cell Lung Cancer.新辅助放化疗后手术治疗局部晚期非小细胞肺癌患者程序性死亡配体 1(PD-L1)的预后价值。
Anticancer Res. 2021 Jun;41(6):3193-3204. doi: 10.21873/anticanres.15106.
9
Prognostic factors for overall survival of stage III non-small cell lung cancer patients on computed tomography: A systematic review and meta-analysis.基于 CT 影像的 III 期非小细胞肺癌患者总生存预后因素的系统评价和荟萃分析。
Radiother Oncol. 2020 Oct;151:152-175. doi: 10.1016/j.radonc.2020.07.030. Epub 2020 Jul 22.
10
Radiotherapy treatment for lung cancer: Current status and future directions.肺癌放射治疗:现状与未来方向。
Respirology. 2020 Nov;25 Suppl 2:61-71. doi: 10.1111/resp.13870. Epub 2020 Jun 9.